Lung Ultrasound-Guided Emergency Department Management of Acute Heart Failure (BLUSHED-AHF): A Randomized Controlled Pilot Trial.
B-lines
acute heart failure
congestion
lung ultrasound
Journal
JACC. Heart failure
ISSN: 2213-1787
Titre abrégé: JACC Heart Fail
Pays: United States
ID NLM: 101598241
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
11
02
2021
revised:
14
05
2021
accepted:
14
05
2021
pubmed:
12
7
2021
medline:
29
10
2021
entrez:
11
7
2021
Statut:
ppublish
Résumé
The goal of this study was to determine whether a 6-hour lung ultrasound (LUS)-guided strategy-of-care improves pulmonary congestion over usual management in the emergency department (ED) setting. A secondary goal was to explore whether early targeted intervention leads to improved outcomes. Targeting pulmonary congestion in acute heart failure remains a key goal of care. LUS B-lines are a semi-quantitative assessment of pulmonary congestion. Whether B-lines decrease in patients with acute heart failure by targeting therapy is not well known. A multicenter, single-blind, ED-based, pilot trial randomized 130 patients to receive a 6-hour LUS-guided treatment strategy versus structured usual care. Patients were followed up throughout hospitalization and 90 days' postdischarge. B-lines ≤15 at 6 h was the primary outcome, and days alive and out of hospital (DAOOH) at 30 days was the main exploratory outcome. No significant difference in the proportion of patients with B-lines ≤15 at 6 hours (25.0% LUS vs 27.5% usual care; P = 0.83) or the number of B-lines at 6 hours (35.4 ± 26.8 LUS vs 34.3 ± 26.2 usual care; P = 0.82) was observed between groups. There were also no differences in DAOOH (21.3 ± 6.6 LUS vs 21.3 ± 7.1 usual care; P = 0.99). However, a significantly greater reduction in the number of B-lines was observed in LUS-guided patients compared with those receiving usual structured care during the first 48 hours (P = 0.04). In this pilot trial, ED use of LUS to target pulmonary congestion conferred no benefit compared with usual care in reducing the number of B-lines at 6 hours or in 30 days DAOOH. However, LUS-guided patients had faster resolution of congestion during the initial 48 hours. (B-lines Lung Ultrasound-Guided ED Management of Acute Heart Failure Pilot Trial; NCT03136198).
Sections du résumé
OBJECTIVES
The goal of this study was to determine whether a 6-hour lung ultrasound (LUS)-guided strategy-of-care improves pulmonary congestion over usual management in the emergency department (ED) setting. A secondary goal was to explore whether early targeted intervention leads to improved outcomes.
BACKGROUND
Targeting pulmonary congestion in acute heart failure remains a key goal of care. LUS B-lines are a semi-quantitative assessment of pulmonary congestion. Whether B-lines decrease in patients with acute heart failure by targeting therapy is not well known.
METHODS
A multicenter, single-blind, ED-based, pilot trial randomized 130 patients to receive a 6-hour LUS-guided treatment strategy versus structured usual care. Patients were followed up throughout hospitalization and 90 days' postdischarge. B-lines ≤15 at 6 h was the primary outcome, and days alive and out of hospital (DAOOH) at 30 days was the main exploratory outcome.
RESULTS
No significant difference in the proportion of patients with B-lines ≤15 at 6 hours (25.0% LUS vs 27.5% usual care; P = 0.83) or the number of B-lines at 6 hours (35.4 ± 26.8 LUS vs 34.3 ± 26.2 usual care; P = 0.82) was observed between groups. There were also no differences in DAOOH (21.3 ± 6.6 LUS vs 21.3 ± 7.1 usual care; P = 0.99). However, a significantly greater reduction in the number of B-lines was observed in LUS-guided patients compared with those receiving usual structured care during the first 48 hours (P = 0.04).
CONCLUSIONS
In this pilot trial, ED use of LUS to target pulmonary congestion conferred no benefit compared with usual care in reducing the number of B-lines at 6 hours or in 30 days DAOOH. However, LUS-guided patients had faster resolution of congestion during the initial 48 hours. (B-lines Lung Ultrasound-Guided ED Management of Acute Heart Failure Pilot Trial; NCT03136198).
Identifiants
pubmed: 34246609
pii: S2213-1779(21)00232-8
doi: 10.1016/j.jchf.2021.05.008
pmc: PMC8419011
mid: NIHMS1709336
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT03136198']
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
638-648Subventions
Organisme : NHLBI NIH HHS
ID : R34 HL136986
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number R34HL136986. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Pang has received research funding from the Agency for Healthcare Research and Quality (AHRQ), the American Heart Association, BMS, Beckman Coulter, Ortho Diagnostics, and Roche over the last year. Roche provided in-kind support for biomarker analysis for this trial. Dr Ehrman has received research funding from GE Healthcare, CNA Diagnostics, and Blue Cross/Blue Shield of Michigan over the last year. Dr Russell has received research funding from GE Healthcare over the last year. Dr Collins has received research funding from the National Institutes of Health, the Patient-Centered Outcomes Research Institute, the Department of Defense, AHRQ, and Beckman Coulter; and consulting with Boehringer Ingelheim, Ortho Clinical, and Bristol Myers Squibb over the last year. Dr Levy has received research funding from the National Institutes of Health, the Patient-Centered Outcomes Research Institute, AHRQ, the Michigan Health Endowment Fund, Delta Dental, and Michigan Department of Health and Human Services, Cardiosounds, Edwards Lifesciences, Novartis, Pfizer, Siemens, and Beckman Coulter; and consulting with Baim Institute, Cardionomics, Ortho Clinical, Roche, Quidel, and the Michigan Public Health Institute over the last year. Dr Ferre has received consulting with Vave Healthcare, Inc; and course director for 3rd Rock Ultrasound, LLC over the last year. Dr Gargani has received research funding from the Italian Ministry of Health and Regione Toscana; and consultancy honoraria from GE Healthcare, Philips Healthcare, and Caption Health over the last year. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
JACC Cardiovasc Imaging. 2010 Jun;3(6):586-94
pubmed: 20541714
Eur J Heart Fail. 2010 May;12(5):423-33
pubmed: 20354029
J Card Fail. 2021 May;27(5):607-609
pubmed: 33091609
Eur J Cardiovasc Nurs. 2019 Aug;18(6):474-483
pubmed: 31018658
Eur Heart J. 2010 Apr;31(7):832-41
pubmed: 19906690
JAMA Cardiol. 2021 Feb 1;6(2):200-208
pubmed: 33206126
Eur J Heart Fail. 2019 Dec;21(12):1605-1613
pubmed: 31667987
J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239
pubmed: 23747642
Am J Emerg Med. 2006 Oct;24(6):689-96
pubmed: 16984837
Australas J Ultrasound Med. 2015 Nov;18(4):143-145
pubmed: 28191258
Heart. 2020 Dec;106(24):1934-1939
pubmed: 32571960
Circ Heart Fail. 2016 Sep;9(9):
pubmed: 27623769
ESC Heart Fail. 2020 Oct;7(5):2941-2947
pubmed: 32697034
BMC Med Educ. 2009 Jan 12;9:3
pubmed: 19138397
JAMA. 2005 Oct 19;294(15):1944-56
pubmed: 16234501
JAMA. 1989 Feb 10;261(6):884-8
pubmed: 2913385
Eur J Heart Fail. 2019 Jul;21(7):844-851
pubmed: 31218825
Cardiovasc Ultrasound. 2006 Aug 31;4:34
pubmed: 16945139
J Am Coll Cardiol. 2019 Jun 4;73(21):2756-2768
pubmed: 31146820
N Engl J Med. 2019 Aug 22;381(8):716-726
pubmed: 31433919
Eur J Heart Fail. 2019 Dec;21(12):1616-1618
pubmed: 31889424
Int J Cardiol. 2016 Sep 1;218:104-108
pubmed: 27232920
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Eur J Emerg Med. 2013 Oct;20(5):356-60
pubmed: 23263648
Eur J Heart Fail. 2017 Sep;19(9):1154-1163
pubmed: 28557302
Intern Emerg Med. 2012 Feb;7(1):65-70
pubmed: 22033792
Am J Cardiol. 2004 May 15;93(10):1265-70
pubmed: 15135701
Am J Med. 2006 Dec;119(12 Suppl 1):S3-S10
pubmed: 17113398
Eur J Heart Fail. 2014 May;16(5):471-82
pubmed: 24599738
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803
pubmed: 28461007
Int J Cardiol. 2018 Feb 15;253:91-96
pubmed: 29306479
J Crit Care. 2015 Dec;30(6):1395-9
pubmed: 26404955
Cardiovasc Ultrasound. 2014 Jul 04;12:25
pubmed: 24993976
Cardiorenal Med. 2013 Jul;3(2):104-112
pubmed: 23922550
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
Eur J Heart Fail. 2015 Nov;17(11):1172-81
pubmed: 26417699
Eur Heart J. 2017 Aug 7;38(30):2364-2373
pubmed: 28459958
Cardiovasc Ultrasound. 2015 Sep 04;13:40
pubmed: 26337295
Eur J Heart Fail. 2019 Jun;21(6):754-766
pubmed: 30690825
Acad Emerg Med. 2016 Mar;23(3):223-42
pubmed: 26910112
Lancet. 2017 Oct 28;390(10106):1981-1995
pubmed: 28460827
Chest. 2009 Jun;135(6):1433-1439
pubmed: 19188552
Lancet Respir Med. 2014 Aug;2(8):638-46
pubmed: 24998674
Am Heart J. 2020 Sep;227:31-39
pubmed: 32668323
Am J Ther. 2018 Jul/Aug;25(4):e475-e486
pubmed: 29985826
Heart Lung. 2019 May - Jun;48(3):186-192
pubmed: 30448355
Chest. 2015 Jul;148(1):202-210
pubmed: 25654562
JACC Heart Fail. 2019 Oct;7(10):849-858
pubmed: 31582107
J Card Fail. 2005 Apr;11(3):200-5
pubmed: 15812748
N Engl J Med. 2011 Jul 7;365(1):32-43
pubmed: 21732835
Cardiovasc Ultrasound. 2011 Feb 27;9:6
pubmed: 21352576